News

DIAGNOSTICS ACCELERATOR AND TARGET ALS FOUNDATION BIOMARKER DISCOVERY RFP

Alzheimer' Drug Discovery Foundation Biomarker Discovery

Due Date: 3/2/22

Funding $300,000/year for 2 years

Requires collaboration between 2-4 PIs with one being located at a pharmaceutical or biotech company.  They have specific interest in biomarkers that are not imaging or CSF based.

 DIAGNOSTICS ACCELERATOR AND TARGET ALS FOUNDATION BIOMARKER DISCOVERY RFP

Read More

Welter Family Graduate Fellowship

Apply for a Welter Family graduate fellowship for research on Cystic Fibrosis
Applications are due August 13, 2021.

Recently, the Welter Family started an endowment aimed at facilitating discoveries in
cystic fibrosis research, which can include mechanistic studies, drug development,
and/or related diseases that affect those with CF (eg., infections of the lung). The Welter

Read More

Sean Cocchia Rare Disease Research Grant Opportunity

Sean Cocchia Rare Disease Research Grant Opportunity

 

Applications due April 1, 2021.

 

 

Thanks to a gift from a benefactor, Sean Cocchia, we are offering one-time grants (up to $25,000) for research aimed at facilitating discoveries in rare disease research, which can include and is not limited to mechanistic studies, drug development, and/or related processes. The grants will provide financial support to conduct research during the 2020-2021 academic year. I ask that you disseminate this request for applications to members of your research team and other groups that you feel qualified to work in this area of research.

Read More

Leahy-Filipi Family Endowment for Excellence in Neuroscience Research

Leahy-Filipi Family Endowment for Excellence in Neuroscience Research

 

Funding is available through the Leahy-Filipi Family, Notre Dame alumni, to support research in neuroscience. This fellowship will provide a $10,000 fellowship. 

Overall Goals of Leahy Filipi Family Endowment for Excellence in Neuroscience  Research: 

Read More

WFCDD RFA Request for Applications-Now Open

The Warren Center for Drug Discovery invites new proposals for projects that are associated with drug discovery. In particular, projects associated with small molecule synthesis (libraries or molecular probes), hit validation, lead optimization, mid-sized scale up, assay development, protein purification, and ADMET screening. Any disease areas will be considered. Collaborative opportunities exist for the preparation of small molecules and/or computational-derived drug discovery via three cores: Chemical Synthesis & Drug Discovery, Computer-Aided Molecular Design, or Biological Screening and Development core. …

Read More

Welter Family Fellowship

Veronica Hubble, a graduate student in the Melander lab, is the first recipient of the Welter Family graduate fellowship for research on Cystic Fibrous. The Welter Family Fellowship in Science provides financial support to conduct research during the 2019 academic year. This fellowship is aimed at facilitating discoveries in cystic fibrosis research, which can include mechanistic studies, drug development, and/or related diseases that affect those with CF (eg. infections of the lung). Veronica’s proposal was entitled “Using small molecule adjuvants to combat antibiotic resistant bacteria in cystic fibrosis.”

Read More

Spring 2019 The Warren Roundup

As the 2018 academic year comes to an end, a summary of this year's accomplishments is provided in the annual Warren Roundup. First of all, several lead compounds have been identified by Notre Dame researchers and are undergoing preclinical evaluation, in hopes of identifying investigational new drugs (IND) for clinical evaluation.  …

Read More

Notre Dame technology licensed worldwide: Hsiri Therapeutics enters into a license and research collaboration agreement with Shionogi &Co., Ltd. for the treatment of mycobacterial diseases

University of Notre Dame licensee Hsiri Therapeutics, Inc., with its corporate headquarters located in Media, PA, has entered into a license agreement with Shionogi & Co., Ltd. regarding a collaborative licensing, research and development program to discover and develop novel therapeutics for non-tuberculous mycobacterial (NTM

Read More